Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 DDI Study in Advanced NSCLC
NCT05926180Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from time zero to last measurable concentration and 3 more. Started Jul 2023; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05926180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926180.